Stockscreener 앱 받기
23.89
1.90%
0.445
시간 외 거래:
23.90
0.005
+0.02%
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Zymeworks Inc. (ZYME) reports Q4 loss, lags revenue estimates - MSN
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach - TipRanks
Experimental breast cancer drug shrinks tumors in 6 weeks at AACR 2026 - Stock Titan
Zymeworks to present clinical data on cancer drug candidate at AACR - Investing.com India
Zymeworks to present clinical data on cancer drug candidate at AACR By Investing.com - Investing.com South Africa
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting - TipRanks
Zymeworks to Present Clinical and Preclinical Data on ADC - GlobeNewswire
New cancer drug conjugates aim at tough RAS tumors in Zymeworks data - Stock Titan
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Prosight Management LP Cuts Stake in Zymeworks Inc. $ZYME - MarketBeat
Value Recap: Does Zymeworks Inc have strong EBITDA marginsTrade Analysis Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Zymeworks (NASDAQ:ZYME) Trading Up 9.7%What's Next? - MarketBeat
Assessing Zymeworks (ZYME) Valuation After Q4 Updates And Improved Clinical And Funding Outlook - Sahm
Zymeworks (ZYME) Price Target Raised to $48 by Evercore ISI Grou - GuruFocus
Will Zymeworks' (ZYME) Wider Losses and ESOP Shelf Offering Recast Its Long-Term Equity Story? - Sahm
Zymeworks (NASDAQ:ZYME) Price Target Raised to $46.00 - MarketBeat
Zymeworks (ZYME) Rating Maintained, Price Target Raised to $46 b - GuruFocus
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade - MarketBeat
Forecasting The Future: 4 Analyst Projections For Zymeworks - Benzinga
Zymeworks (ZYME) Target Price Raised by Leerink Partners to $58 - GuruFocus
Stifel raises Zymeworks stock price target on royalty deal value By Investing.com - Investing.com Canada
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position - Investing.com Nigeria
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Australia
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience By GuruFocus - Investing.com Canada
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal By Investing.com - Investing.com Canada
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com South Africa
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Zymeworks Q4 2025 shows revenue growth, net loss reduction - Investing.com UK
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens - AlphaStreet
Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Zymeworks Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-03-02 - Seeking Alpha
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - Koreabizwire
Zymeworks Reports FY25 Results, Secures $250 Million Royalty Financing - Nasdaq
Zymeworks Monetizes Ziihera Royalties to Boost Liquidity - TipRanks
Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity - TipRanks
Zymeworks 2025 10-K: $106M Revenue, $(1.08) EPS - TradingView
Zymeworks Inc. Q4 Loss Widens - Nasdaq
Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing - Stock Titan
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
Zymeworks Inc. Reports Financial Results for 2025 and Updates on Ziihera® Development and Strategic Plans - Quiver Quantitative
1.20%
0.06%
자본화:
|
볼륨(24시간):